title: Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.
abstract: Vandetanib (ZD6474, Zactima™) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QC interval prolongation, and hypertension. In a few randomized, double-blinded studies, cutaneous adverse events including these general symptoms have been reported, but there are only a few reports on the photosensitivity reaction to vandetanib domestically as conducted by dermatologists. In this report, we describe two cases of photosensitivity reactions induced by vandetanib. After improvement with steroid and antihistamine, the photosensitivity reaction was redeveloped by sequential treatment with docetaxel.
authors.affiliation: Department of Dermatology, Gachon University of Medicine and Science, Gil Hospital, Incheon, Korea.
authors.forename: Young-Min
authors.initials: YM
authors.lastname: Son
authors.forename: Joo-Young
authors.initials: JY
authors.lastname: Roh
authors.forename: Eun-Kyung
authors.initials: EK
authors.lastname: Cho
authors.forename: Jong-Rok
authors.initials: JR
authors.lastname: Lee